BioSpace News Archive

Arrakis Receives $190 Million Upfront Cash Payment with Potential for Multi-Billion Dollar Future Payments

The Exclusive Research Report on Unit-Dose Respiratory Medications with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029″.

The Exclusive Research Report on Naloxone Hydrochloride with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029″.

The Exclusive Research Report on Methotrexate with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029″.

The Exclusive Research Report on Cell Freezing Media with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029″.

The Exclusive Research Report on External Beam Radiation Therapy Devices with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029″.

Viriom, Inc. announced the initiation of a Phase 2 clinical study to evaluate the efficacy of elsulfavirine in adults with moderate manifestations of COVID-19.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides an update on its upcoming Annual General Meeting, scheduled to be held at the offices of Shakespeare Martineau at 60 Gracechurch Street, London EC3V 0HR, United Kingdom at 10.30 a.m. on April 16, 2020.

Immunovia AB announced that the company’s Lung Cancer collaboration with a global pharmaceutical company has been terminated.

Advancements in science and technology has tremendously impacted medical science.